WASHINGTON, Feb. 16, 2024 /PRNewswire/ — The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the U.S. Food and Drug Administration (FDA) decision to approve Iovance Biotherapeutics’ AMTAGVI™ (lifileucel) for the treatment of…
Melanoma Research Alliance Applauds FDA Approval of First Cellular Therapy in Melanoma
This post was originally published on this site